These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6143506)

  • 41. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson DG; Woerner MG; Alvir JM; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Bilder R; Goldman R; Lieberman JA
    Am J Psychiatry; 1999 Apr; 156(4):544-9. PubMed ID: 10200732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of symptoms in neuroleptic-naive patients with schizophrenia and related psychotic disorders before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Psychiatry Res; 2001 Dec; 105(1-2):97-105. PubMed ID: 11740979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of maintenance use of anticholinergic agents.
    Double DB; Warren GC; Evans M; Rowlands RP
    Acta Psychiatr Scand; 1993 Nov; 88(5):381-4. PubMed ID: 7905226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance.
    Kay SR; Singh MM
    Arch Gen Psychiatry; 1989 Aug; 46(8):711-8. PubMed ID: 2568824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The concept of supersensitivity psychosis.
    Kirkpatrick B; Alphs L; Buchanan RW
    J Nerv Ment Dis; 1992 Apr; 180(4):265-70. PubMed ID: 1348269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
    Sharma RP; Javaid JI; Pandey GN; Janicak PG; Davis JM
    Biol Psychiatry; 1991 Sep; 30(5):459-66. PubMed ID: 1657221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroleptic withdrawal in schizophrenic patients. A review of the literature.
    Gilbert PL; Harris MJ; McAdams LA; Jeste DV
    Arch Gen Psychiatry; 1995 Mar; 52(3):173-88. PubMed ID: 7872841
    [No Abstract]   [Full Text] [Related]  

  • 48. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.
    van Kammen DP; Bunney WE; Docherty JP; Marder SR; Ebert MH; Rosenblatt JE; Rayner JN
    Am J Psychiatry; 1982 Aug; 139(8):991-7. PubMed ID: 7091448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationships between medication treatments and neuropsychological test performance in schizophrenia.
    Sweeney JA; Keilp JG; Haas GL; Hill J; Weiden PJ
    Psychiatry Res; 1991 Jun; 37(3):297-308. PubMed ID: 1679950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
    Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
    Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
    Tuninger E; Levander S
    Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Physostigmine and lithium response in the schizophrenias.
    Edelstein P; Schultz JR; Hirschowitz J; Kanter DR; Garver DL
    Am J Psychiatry; 1981 Aug; 138(8):1078-81. PubMed ID: 7258385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.
    Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P
    J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.
    Dencker SJ; Lepp M; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():64-76. PubMed ID: 6105763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.
    Okuma T; Yamashita I; Takahashi R; Itoh H; Otsuki S; Watanabe S; Sarai K; Hazama H; Inanaga K
    Acta Psychiatr Scand; 1989 Sep; 80(3):250-9. PubMed ID: 2573234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.
    Janowsky DS; el-Yousel MK; Davis JM; Sekerke HJ
    Arch Gen Psychiatry; 1973 Feb; 28(2):185-91. PubMed ID: 4630714
    [No Abstract]   [Full Text] [Related]  

  • 57. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
    Spina E; De Domenico P; Ruello C; Longobardo N; Gitto C; Ancione M; Di Rosa AE; Caputi AP
    Int Clin Psychopharmacol; 1994; 9(4):281-5. PubMed ID: 7868850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attitudes of patients with schizophrenia toward placebo-controlled clinical trials.
    Hummer M; Holzmeister R; Kemmler G; Eder U; Hofer A; Kurzthaler I; Oehl M; Weiss E; Fleischhacker WW
    J Clin Psychiatry; 2003 Mar; 64(3):277-81. PubMed ID: 12716268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
    Duinkerke SJ; Botter PA; Jansen AA; van Dongen PA; van Haaften AJ; Boom AJ; van Laarhoven JH; Busard HL
    Br J Psychiatry; 1993 Oct; 163():451-5. PubMed ID: 7902766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psychotic recurrence after antipsychotic discontinuation.
    Zipursky RB
    Am J Psychiatry; 2002 Aug; 159(8):1441-2; author reply 1442. PubMed ID: 12153856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.